Abstract
This study addressed whether psychopharmacologic and psychotherapeutic treatment of depressed HIV? women met standards defined in the best practice literature, and tested hypothesized predictors of standardconcordant care. 1,352 HIV-positive women in the multicenter Women's Interagency HIV Study were queried about depressive symptoms and mental health service utilization using standards published by the American Psychiatric Association and the Agency for Healthcare Research and Quality to define adequate depression treatment. We identified those who: (1) reported clinically significant depressive symptoms (CSDS) using Centers for Epidemiological Studies-Depression Scale scores of C16≤ or (2) had lifetime diagnoses of major depressive disorder (MDD) assessed by World Mental Health Composite International Diagnostic Interviews plus concurrent elevated depressive symptoms in the past 12 months. Adequate treatment prevalence was 46.2 % (n = 84) for MDD and 37.9 % (n = 211) for CSDS. Multivariable logistic regression analysis found that adequate treatment was more likely among women who saw the same primary care provider consistently, who had poorer self-rated role functioning, who paid out-of-pocket for healthcare, and who were not African American or Hispanic/Latina. This suggests that adequate depression treatment may be increased by promoting healthcare provider continuity, outreaching individuals with lower levels of reported role impairment, and addressing the specific needs and concerns of African American and Hispanic/Latina women.X
Original language | English (US) |
---|---|
Pages (from-to) | 1094-1102 |
Number of pages | 9 |
Journal | AIDS and Behavior |
Volume | 18 |
Issue number | 6 |
DOIs | |
State | Published - 2014 |
Fingerprint
Keywords
- Depression treatment
- Psychopharmacology
- Psychotherapy
- Women and HIV
ASJC Scopus subject areas
- Public Health, Environmental and Occupational Health
- Infectious Diseases
- Social Psychology
- Medicine(all)
Cite this
Do HIV-positive women receive depression treatment that meets best practice guidelines? / Cook, Judith A.; Burke-Miller, Jane K.; Grey, Dennis D.; Cocohoba, Jennifer; Liu, Chenlong; Schwartz, Rebecca M.; Golub, Elizabeth T.; Anastos, Kathryn; Steigman, Pamela J.; Cohen, Mardge H.
In: AIDS and Behavior, Vol. 18, No. 6, 2014, p. 1094-1102.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Do HIV-positive women receive depression treatment that meets best practice guidelines?
AU - Cook, Judith A.
AU - Burke-Miller, Jane K.
AU - Grey, Dennis D.
AU - Cocohoba, Jennifer
AU - Liu, Chenlong
AU - Schwartz, Rebecca M.
AU - Golub, Elizabeth T.
AU - Anastos, Kathryn
AU - Steigman, Pamela J.
AU - Cohen, Mardge H.
PY - 2014
Y1 - 2014
N2 - This study addressed whether psychopharmacologic and psychotherapeutic treatment of depressed HIV? women met standards defined in the best practice literature, and tested hypothesized predictors of standardconcordant care. 1,352 HIV-positive women in the multicenter Women's Interagency HIV Study were queried about depressive symptoms and mental health service utilization using standards published by the American Psychiatric Association and the Agency for Healthcare Research and Quality to define adequate depression treatment. We identified those who: (1) reported clinically significant depressive symptoms (CSDS) using Centers for Epidemiological Studies-Depression Scale scores of C16≤ or (2) had lifetime diagnoses of major depressive disorder (MDD) assessed by World Mental Health Composite International Diagnostic Interviews plus concurrent elevated depressive symptoms in the past 12 months. Adequate treatment prevalence was 46.2 % (n = 84) for MDD and 37.9 % (n = 211) for CSDS. Multivariable logistic regression analysis found that adequate treatment was more likely among women who saw the same primary care provider consistently, who had poorer self-rated role functioning, who paid out-of-pocket for healthcare, and who were not African American or Hispanic/Latina. This suggests that adequate depression treatment may be increased by promoting healthcare provider continuity, outreaching individuals with lower levels of reported role impairment, and addressing the specific needs and concerns of African American and Hispanic/Latina women.X
AB - This study addressed whether psychopharmacologic and psychotherapeutic treatment of depressed HIV? women met standards defined in the best practice literature, and tested hypothesized predictors of standardconcordant care. 1,352 HIV-positive women in the multicenter Women's Interagency HIV Study were queried about depressive symptoms and mental health service utilization using standards published by the American Psychiatric Association and the Agency for Healthcare Research and Quality to define adequate depression treatment. We identified those who: (1) reported clinically significant depressive symptoms (CSDS) using Centers for Epidemiological Studies-Depression Scale scores of C16≤ or (2) had lifetime diagnoses of major depressive disorder (MDD) assessed by World Mental Health Composite International Diagnostic Interviews plus concurrent elevated depressive symptoms in the past 12 months. Adequate treatment prevalence was 46.2 % (n = 84) for MDD and 37.9 % (n = 211) for CSDS. Multivariable logistic regression analysis found that adequate treatment was more likely among women who saw the same primary care provider consistently, who had poorer self-rated role functioning, who paid out-of-pocket for healthcare, and who were not African American or Hispanic/Latina. This suggests that adequate depression treatment may be increased by promoting healthcare provider continuity, outreaching individuals with lower levels of reported role impairment, and addressing the specific needs and concerns of African American and Hispanic/Latina women.X
KW - Depression treatment
KW - Psychopharmacology
KW - Psychotherapy
KW - Women and HIV
UR - http://www.scopus.com/inward/record.url?scp=84905577511&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84905577511&partnerID=8YFLogxK
U2 - 10.1007/s10461-013-0679-6
DO - 10.1007/s10461-013-0679-6
M3 - Article
C2 - 24402689
AN - SCOPUS:84905577511
VL - 18
SP - 1094
EP - 1102
JO - AIDS and Behavior
JF - AIDS and Behavior
SN - 1090-7165
IS - 6
ER -